Evolus Valuation Multiples

Evolus Overview

About Evolus

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Founded

2012

HQ

Employees

332

Website

evolus.com

Sectors

Health & BeautyBioTech

Financials (LTM)

Revenue: $307M

EBITDA: ($18M)

EV

$406M

Valuation Multiples

Multiples.vc

Start free trial

Evolus Financials

Evolus reported last 12-month revenue of $307M and negative EBITDA of ($18M).

In the same LTM period, Evolus generated $204M in gross profit, ($18M) in EBITDA losses, and had net loss of ($47M).

Evolus P&L

In the most recent fiscal year, Evolus reported revenue of $297M and EBITDA of ($23M).

Evolus expects next 12-month revenue of XXX and NTM EBITDA of XXX

Evolus Stock Performance

Evolus has current market cap of $305M, and enterprise value of $406M.

Evolus' stock price is $4.69.

Evolus Valuation Multiples

Evolus trades at 1.3x EV/Revenue multiple, and (23.1x) EV/EBITDA.

Evolus Financial Valuation Multiples

As of April 20, 2026, Evolus has market cap of $305M and EV of $406M.

Equity research analysts estimate Evolus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Evolus has a P/E ratio of (6.5x).

Evolus Margins & Growth Rates

Evolus' revenue in the last 12 month grew by 13%.

Evolus' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.7M for the same period.

Evolus' rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Evolus' rule of X is 26% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Evolus Public Comps

See public comps and valuation multiples for other Health & Beauty comps.

Evolus M&A Activity

Evolus acquired XXX companies to date.

Last acquisition by Evolus was on XXXXXXXX, XXXXX. Evolus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Evolus Investment Activity

Evolus invested in XXX companies to date.

Evolus made its latest investment on XXXXXXXX, XXXXX. Evolus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).